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Abstract
Background: Metabolic syndrome (MetS) is potentially effective measures to identify individuals
at risk of coronary heart disease (CHD) and type 2 diabetes. To verify the hypothesis that smoking
cessation may increase the risk of MetS, a follow-up study taking drinking habit into account was
conducted for the examinees at one health checkup institution.
Methods: Subjects were the examinees who visited the Institution for Disease Prevention and
Health Checkup, Seirei Mikatabara Hospital for annual health checkup from January 2003 to
December 2006. Among them, 5,872 smokers (5,479 men, 93.3%) free from MetS at the first year
in two consecutive years were selected. For the long term follow-up, the risk of MetS among those
who maintained their nonsmoking status for 1 or 2 additional years was evaluated.
Results: Relative to non-quitters, quitters showed a significantly elevated adjusted hazard ratio
(aHR) of MetS in two consecutive years (aHR = 2.09, 95% confidence interval: 1.43–3.04, P <
0.001). The aHR was higher among the quitters who had a drinking habit at the first year (aHR =
2.42, 95% CI: 1.48–3.94, P < 0.001). Analyses for 1 or 2 additional years of follow-up revealed that
this significant increase in risk of MetS was transient.
Conclusion:  The present study revealed that smoking cessation elevated the risk of MetS
significantly, especially among drinkers. Although this detrimental effect of smoking cessation was
found to be during only a short term, our results suggested that we should take measures,
presumably including interventions for alcohol cessation, not to expose smoking quitters to this
adverse effect. Further investigations are required to confirm our findings.
Background
Facing the era of aging society, Japanese nations have
come to pay more and more attention to the metabolic
syndrome (MetS), which was recently defined by National
Cholesterol Education Program (NECP) to help identify
individuals at risk of coronary heart disease (CHD) and
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type 2 diabetes [1]. In the preceding decades, lifestyles
changed: sedentary lifestyles became more and more com-
mon; people got used to ride a car when they moved,
where they had less opportunity to walk, contributing to
the increasing development of diabetes or MetS [2].
Recently, it was reported by Japanese researchers that cig-
arette smoking increased the risk of MetS, and they also
found that body weight gain was higher in smokers who
quit smoking compared with never smokers [3]. It is well
known that people gain weight after quitting smoking;
from many clinical experiences, it seemed probable that
smoking cessation would raise the risk of MetS.
Some studies reported a possible association between
alcohol intake and risk of MetS [4], but this association is
still controversial. Other reports also demonstrated the
beneficial effect of alcohol intake on the risk of MetS, sug-
gesting that this relationship is rather complex [5,6]. Alco-
hol consumption was reported to have favorable effects
on plasma high density lipoprotein cholesterol (HDL-C)
levels [7] and insulin sensitivity, as well as unfavorable
effects to increase plasma triglyceride (TG) levels or ele-
vate blood pressure (BP). The association between alcohol
and weight gain is still discussed.
In this study, to verify the hypothesis that smoking cessa-
tion may increase the risk of MetS and alcohol intake
might also modulate its risk, a follow-up study was con-
ducted for health checkup examinees at Institution for
Disease Prevention and Health Checkup, Seirei Mikata-
bara Hospital.
Methods
Study Subjects
The study subjects were the health checkup examinees
who visited the Institution for Disease Prevention and
Health Checkup, Seirei Mikatabara Hospital for annual
health checkup from January 2003 to December 2006. In
total, 15,508 examinees (10,243 men, 66.0%) in year
2003, 15,584 (10,123 men, 65.0%) in 2004, 16,322
(10,492 men, 64.3%) in 2005, and 16,586 (10,630 men,
64.1%) in 2006 visited this annual health checkup. Most
of the examinees visited the institute for health checkup
annually. Among them, 5,872 subjects (5,479 men,
93.3%) who visited it in two consecutive years and those
who smoked and did not suffer from MetS or diabetes
mellitus (DM) in the first year were selected from the
whole examinees. Among these selected examinees, 185
subjects (177 men, 95.7%) became MetS. Table 1 shows
the characteristics of the selected study subjects. For the
long term follow-up, the risk of MetS among those who
smoked in the first year and quitted smoking in the sec-
ond year, and maintained their nonsmoking status for
one or two additional years was evaluated.
Data collection
Annual health checkup at the institute included medical
examination and interviews about medical history and
health-related behavior, consisting of data on smoking
status, alcohol intake, and regular physical activity. BP
measurements and anthropometric measurements of
height and weight were done by trained examiners. Fast-
ing serum glucose (FSG), HDL-C, and TG levels were
determined in serum samples obtained at the time of the
medical examination.
Diagnostic criteria
The diagnosis of MetS was defined according to the mod-
ified Japanese criteria (criteria defined by Japanese Society
for the Study of Obesity (JASSO)) [8] as follows: For the
major criteria, overall obesity was defined as body mass
index (BMI) of ≥ 25 kg/m2 instead of waist circumference
(WC) as described in the previous Japanese report [3],
because we could not obtain the data of WC in this popu-
lation. For the minor criteria, we investigated the presence
of three metabolic risk factors: hypertension, dyslipi-
demia, and impaired fasting glucose. Hypertension repre-
sented elevated BP: systolic BP (sBP) ≥ 130 mmHg and/or
diastolic BP (dBP) ≥ 85 mmHg. Dyslipidemia represented
hypertriglyceridemia (fasting TG ≥ 150 mg/dl), and/or
low HDL-C (< 40 mg/dl). Impaired fasting glucose repre-
sented hyperglycemia: FSG concentration ≥ 110 mg/dl.
Those who met the obesity criteria (major criteria) and no
less than two of three metabolic risk factors (minor crite-
ria: hypertension, dyslipidemia and impaired fasting glu-
cose) were diagnosed as having MetS. Those with FSG
concentration ≥ 126 mg/dl at baseline were diagnosed as
having DM and excluded. Those who became diabetic in
the second year were excluded from MetS. Smoking cessa-
tion was defined for those who stated to be current smok-
ers at questionnaire in the first year, and stated to have
quitted smoking or to be no current smokers in the second
year. Those who smoked in the first year and quitted in
the second year are defined as smoking "quitters," and the
rest are called "non-quitters." Among the quitters, those
who stated to be habitual alcohol drinkers in the second
year were defined as "drinkers."
Evaluation of MetS components
We categorized the examinees who became MetS in the
second year among smoking quitters (n = 33) according to
the combinations of fulfilled MetS criteria components in
the first year (before cessation) and in the second year
(after cessation), and evaluated which component con-
tributed to the occurrence of MetS in each case.
Statistical analysis
The adjusted hazard ratio (aHR) and 95% confidence
interval (95% CI) were estimated with a Cox's propor-
tional hazard model adjusted by age and sex. DifferencesBMC Public Health 2009, 9:263 http://www.biomedcentral.com/1471-2458/9/263
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of the MetS parameters of two groups were tested by a
multiple linear regression model. Statistical analysis was
conducted with STATA version 7 (STATA Corporation,
College Station, TX).
Ethics
This study was approved by the Ethics Committee of Seirei
Mikatabara Hospital.
Results
Table 2 shows the risk of MetS according to smoking sta-
tus. When those who continued smoking were defined as
the reference, those who quitted smoking showed signifi-
cantly or nearly significantly elevated aHR for MetS in any
two consecutive years (aHR = 2.09, 95% CI: 1.43–3.05, P
< 0.001 in years 2003–2006 total: aHR = 2.60, 95% CI:
1.34–5.04, P = 0.005 in years 2003–2004; aHR = 1.84,
95% CI: 1.01–3.37, P = 0.048 in years 2004–2005; aHR =
1.92, 95% CI: 0.94–3.93, P = 0.073 in years 2005–2006).
To investigate the main factor contributing to this risk ele-
vation of MetS among smoking quitters, we next com-
pared each MetS parameters of smoking quitters with
those of non-quitters by multiple linear regression model
(Table 3, 4). In total, increase in HDL-C levels were signif-
icantly higher in smoking quitters than in non-quitters (P
< 0.001), while increases in FSG (P < 0.001), BP (both sBP
and dBP) (P < 0.001 and P < 0.001, respectively) and BMI
(P < 0.001) were significantly higher in smoking quitters
than in non-quitters (Table 3). To exclude the possibility
that changes in these parameters were just the reflection of
BMI increase, we calculated the differences of these
parameters adjusted by sex, age and increase in BMI by
multiple regression model, all of which still remained sig-
nificant; HDL-C levels (P < 0.001); FSG (P < 0.001); sBP
(P < 0.001) and dBP (P < 0.001) (Table 4).
To clarify the factors contributing to the elevation of MetS
risk among smoking quitters, we calculated the distribu-
tion of fulfilled MetS criteria components before and after
quitting smoking among quitters who got MetS in the sec-
Table 1: Baseline characteristics of the selected study subjects according to smoking status.
Non-quitter Quitter
Men Women Total Men Women Total
n 4967 347 5314 512 46 558
Agea 50.2 ± 8.6 49.4 ± 8.1 50.1 ± 8.6 51.5 ± 9.2 50.1 ± 8.3 51.4 ± 9.1
Lifestyle behaviors
Habitual drinkers 3765 (75.8%) 174 (50.1%) 3939 (74.1%) 379 (74.0%) 16 (34.8%) 395 (70.8%)
Current smokers 4967 (100.0%) 347 (100.0%) 5314 (100.0%) 512 (100.0%) 46 (100.0%) 558 (100.0%)
Components for MetS
HDL cholesterol (mg/dL)
< 40 554 (11.2%) 10 (2.9%) 564 (10.6%) 53 (10.4%) 3 (6.5%) 56 (10.0%)
≥ 40 4413 (88.8%) 337 (97.1%) 4750 (89.4%) 459 (89.6%) 43 (93.5%) 502 (90.0%)
Fasting triglyceride (mg/dL)
< 150 3612 (72.7%) 300 (86.5%) 3912 (73.6%) 391 (76.4%) 39 (84.8%) 430 (77.1%)
≥ 150 1355 (27.3%) 47 (13.5%) 1402 (26.4%) 121 (23.6%) 7 (15.2%) 128 (22.9%)
Fasting serum glucose (mg/dL)
< 110 4555 (91.7%) 327 (94.2%) 4882 (91.9%) 471 (92.0%) 45 (97.8%) 516 (92.5%)
≥ 110 412 (8.3%) 20 (5.8%) 432 (8.1%) 41 (8.0%) 1 (2.2%) 42 (7.5%)
Systolic blood pressure (mmHg)
< 130 3957 (79.7%) 308 (88.8%) 4265 (80.3%) 408 (79.7%) 40 (87.0%) 448 (80.3%)
≥ 130 1010 (20.3%) 39 (11.2%) 1049 (19.7%) 104 (20.3%) 6 (13.0%) 110 (19.7%)
Diastolic blood pressure (mmHg)
< 85 4340 (87.4%) 324 (93.4%) 4664 (87.8%) 449 (87.7%) 42 (91.3%) 491 (88.0%)
≥ 85 627 (12.6%) 23 (6.6%) 650 (12.2%) 63 (12.3%) 4 (8.7%) 67 (12.0%)
Body mass index
< 22 2013 (40.5%) 198 (57.1%) 2211 (41.6%) 209 (40.8%) 25 (54.3%) 234 (41.9%)
22 ≤ < 25 2113 (42.5%) 104 (30.0%) 2217 (41.7%) 223 (43.6%) 14 (30.4%) 237 (42.5%)
≥ 25 841 (16.9%) 45 (13.0%) 886 (16.7%) 80 (15.6%) 7 (15.2%) 87 (15.6%)
aData is shown as mean ± standard deviation (SD).BMC Public Health 2009, 9:263 http://www.biomedcentral.com/1471-2458/9/263
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ond year (n = 33). We found that each MetS criterion
turned positive nearly equally after quitting smoking: 15
subjects became hypertensive, 13 subjects became hyperl-
ipidemic (while 2 previously hyperlipidemic subjects
became nonhyperlipidemic), and that 13 subjects devel-
oped impaired fasting glucose, as for minor criteria
(Table 5).
Table 6 shows the risk of MetS according to the combined
status of smoking cessation and alcohol consumption.
When non-quitters who does not drink alcohol were
defined as the reference, smoking quitters who drinks
alcohol showed statistically significant risk increase in
MetS (aHR = 2.42, 95% CI: 1.48–3.94, P < 0.001). The
interaction of quitting smoking and drinking was 2.03
(95% CI: 0.78–3.94, P = 0.146).
We also examined changes in the MetS parameters among
drinkers with those among non-drinkers to investigate the
factors influenced by drinking by multiple linear regres-
sion model, which revealed that none of the parameters
showed statistically significant difference in change
between the two groups (data not shown).
To evaluate the long-term effect of smoking cessation on
the risk of MetS, we checked the aHR of MetS among those
who maintained their nonsmoking status for one or two
additional years during follow-up. For those who main-
tained their nonsmoking status for another year (n = 245
among 3,254 examinees), the aHR of MetS was 1.28 (95%
CI: 0.69–2.38, P = 0.440) (aHR = 1.65, 95% CI: 0.71–
3.87, P = 0.245 in years 2003–2005 [n = 109 among 1,609
examinees]; aHR = 1.01, 95% CI: 0.41–2.52, P = 0.981 in
years 2004–2006 [n = 136 among 1,645 examinees]), and
for those who maintained their nonsmoking status for
two additional years (in years 2003–2006) (n = 28 among
1,496 examinees), the aHR of MetS was 0.74 (95% CI:
0.10–5.37, P = 0.769).
Discussion
Our study result revealed that smoking cessation
increased the risk of MetS, and alcohol intake might pos-
sibly add to this risk elevation in male smoking quitters.
It has been reported that the mechanisms in which smok-
ing cessation promotes weight gain is explained by
increased energy intake, decreased resting metabolic rate,
Table 2: Adjusted hazard ratio (aHR)a and 95% confidence intervals (95% CIs) of metabolic syndrome according to smoking status.
Men Women Total
Non-quitter Quitter Non-quitter Quitter Non-quitter Quitter
n 4972 496 342 62 5314 558
MetS 145 32 7 1 152 33
aHR 12 . 2 01 0 . 7 5 12 . 0 9
95% CI Reference 1.50–3.23*** Reference 0.09–6.14 Reference 1.43–3.05***
Major Criteria (BMI) 881 116 57 7 938 123
aHR 11 . 3 61 0 . 6 8 11 . 2 9
95% CI Reference 1.12–1.66** Reference 0.31–1.48 Reference 1.07–1.56**
Hypertension 1150 165 43 6 1193 171
aHR 11 . 3 41 0 . 7 5 11 . 3 0
95% CI Reference 1.14–1.58*** Reference 0.32–1.76 Reference 1.11–1.53**
Dyslipidemia 1647 170 43 4 1690 174
aHR 11 . 0 41 0 . 5 0 11 . 0 2
95% CI Reference 0.89–1.22 Reference 0.18–1.40 Reference 0.87–1.19
Impaired Fasting Glucose 504 68 17 7 521 75
aHR 11 . 2 81 2 . 2 2 11 . 3 2
95% CI Reference 0.99–1.65 Reference 0.92–5.37 Reference 1.04–1.69*
Minor Criteriab 584 84 15 3 599 87
aHR 11 . 3 71 1 . 0 5 11 . 3 5
95% CI Reference 1.09–1.72** Reference 0.30–3.64 Reference 1.08–1.69**
*: P < 0.05, **: P < 0.01, ***:P < 0.001.
aAdjusted for sex and age (total), or age (men and women).
b Minor criteria include hypertension, dyslipidemia and impaired fasting glucose.BMC Public Health 2009, 9:263 http://www.biomedcentral.com/1471-2458/9/263
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decreased physical activity, and increased lipoprotein
lipase activity [9-12]. It is also reported that nicotine exerts
its influence on lipid metabolism through the antiestro-
genic effects, inducing lypolysis by stimulating the sympa-
thetic nervous system, leading to a consequent increase in
plasma free fatty acids [13,14].
In this study, we observed the higher aHR of MetS in
smoking quitters than in non-quitters, which seemingly
suggested the effect of smoking cessation in the occur-
rence of MetS. Our further analyses about the MetS
parameters showed that levels of HDL-C, FSG, sBP and
dBP, and BMI elevated significantly after smoking cessa-
tion. To exclude the effect of weight gain and evaluate the
true effect of smoking cessation on the risk of MetS, we
also calculated the differences in MetS parameters before
and after smoking cessation adjusted by BMI increase,
which remained significant. In this analysis, significantly
lower fasting TG level among smoking quitters than in
non-quitters (P < 0.05) was observed. This might reflect
some early beneficial effect of smoking cessation, in
accordance with the conclusions of a review of 54 pub-
lished studies, which supported a significant dose-
response effect between smoking and increased serum TG
levels [15]. Although our further analyses among subjects
with MetS detected significant difference only in HDL-C
levels, FSG levels and BMI, which might be partly attribut-
able to the relatively small number of the subjects, our
examination of MetS criteria positive rates before and after
quitting smoking revealed that only a part of the subjects
getting MetS are explained by weight gain (6 of 33 subjects
are attributable to weight gain), and the rest of them are
due to acquiring other MetS criteria components. As for
the association between smoking cessation and these
MetS related factors, following facts are known. The fact
that smoking cessation promotes weight gain is already
well known [9-11], and our study results confirmed this
relation. It is also reported that BP elevation and increased
prevalence of hypertension is observed after smoking ces-
sation [16-18]. These BP elevations after smoking cessa-
Table 3: Multiple linear regression coefficients of smoking cessation for changes in metabolic syndrome parameters after smoking 
cessation.
Men Women Total
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
All Subjects
(quitter 558, non-quitter 5314)
HDL cholesterol (mg/dL) 2.3 (1.6, 3.0)*** 1.6 (-1.1, 4.3) 2.2 (1.6, 2.9)***
Fasting triglyceride (mg/dL) 3.6 (-3.6, 10.8) 7.5 (-5.9, 20.9) 3.9 (-2.9, 10.7)
Fasting serum glucose (mg/dL) 2.3 (1.7, 3.0)*** 2.7 (0.6, 4.8)* 2.4 (1.8, 3.0)***
Systolic blood pressure (mmHg) 4.0 (2.8, 5.1)*** 0.0 (-3.6, 3.6) 3.7 (2.6, 4.7)***
Diastolic blood pressure (mmHg) 2.7 (1.8, 3.5)*** 0.6 (-2.2, 3.5) 2.5 (1.7, 3.3)***
Body mass index 0.5 (0.5, 0.6)*** 0.3 (0.1, 0.5) 0.5 (0.4, 0.6)***
MetS
(quitter 33, non-quitter 152)
HDL cholesterol (mg/dL) 3.7 (1.2, 6.1)** 13.3 (-32.2, 58.7) 3.9 (1.5, 6.3)**
Fasting triglyceride (mg/dL) -10.9 (-46.7, 25.0) -36.9 (-190.7, 116.9) -11.9 (-46.9, 23.0)
Fasting serum glucose (mg/dL) 3.0 (0.1, 5.8)* 17.5 (-53.2, 88.1) 3.3 (0.5, 6.2)*
Systolic blood pressure (mmHg) 2.9 (-2.4, 8.3) 11.1 (-20.4, 42.5) 3.0 (-2.2, 8.2)
Diastolic blood pressure (mmHg) 2.2 (-1.8, 6.1) 24.3 (-18.2, 66.8) 2.7 (-1.2, 6.6)
Body mass index 0.6 (0.3, 0.9)*** 3.1 (1.0, 5.1)* 0.6 (0.4, 0.9)***
without MetS
(quitter 525, non-quitter 5162)
HDL cholesterol (mg/dL) 2.2 (1.5, 2.9)*** 1.4 (-1.3, 4.1) 2.2 (1.5, 2.9)***
Fasting triglyceride (mg/dL) 3.9 (-3.5, 11.3) 8.4 (-5.2, 22.0) 4.2 (-2.7, 11.2)
Fasting serum glucose (mg/dL) 2.2 (1.5, 2.8)*** 2.4 (0.3, 4.5)* 2.2 (1.5, 2.8)***
Systolic blood pressure (mmHg) 3.9 (2.7, 5.0)*** -0.1 (-3.7, 3.5) 3.5 (2.4, 4.6)***
Diastolic blood pressure (mmHg) 2.6 (1.7, 3.5)*** 0.2 (-2.7, 3.1) 2.4 (1.6, 3.2)***
Body mass index 0.5 (0.4, 0.6)*** 0.2 (0.0, 0.5) 0.5 (0.4, 0.5)***
Coefficients are adjusted for sex and age by multiple linear regression.
95% CIs are shown in parentheses.
*: P < 0.05, **: P < 0.01, ***:P < 0.001.BMC Public Health 2009, 9:263 http://www.biomedcentral.com/1471-2458/9/263
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tion are supposed to be explained by increase in weight
due to increase in food intake, or increase in stress [16].
Recent study in Korea revealed cigarette smoking as one of
the modifiable risk factors for type 2 DM, which demon-
strated the transient increase in the risk of diabetes with
smoking cessation that remained significant after adjust-
ment for weight change [19]. It is also shown that smok-
ing decreases HDL-C levels through the decrease in lecitin
cholesterol acyl-transferase (LCAT) and alteration in the
activities of cholesterol ester transfer protein (CETP) and
hepatic lipase (HL) [20,21]. Our study results were in the
same trends to the previous reports, suggesting that we
should take measures not to expose smoking quitters to
these adverse effects [22], although these effects seem to
be only transient.
To date, some groups examined the association between
alcohol intake and risk of MetS [3,4,23,24]. Most of them
resulted in insignificant association, or even some protec-
tive effect of alcohol against MetS was observed. In this
study, we did not observe significantly higher risk of MetS
after smoking cessation among drinkers than among non-
drinkers (data not shown). However, our combined anal-
ysis of smoking cessation and alcohol intake revealed that
those who quitted smoking and drank alcohol were at
highest risk of MetS, and possible interaction between
smoking cessation and alcohol intake was observed
although statistically insignificant, suggesting that alcohol
intake added to the detrimental effect of smoking cessa-
tion on the occurrence of MetS. Our further analyses
about the differences in each MetS parameters according
to the alcohol consumption status among smoking quit-
ters revealed the tendency that the levels of HDL-C, sBP
and dBP were higher in alcohol drinkers, although none
of which were statistically significant (data not shown).
The seemingly contrast findings of the statistically insig-
nificant differences in the levels of these MetS parameters
according to alcohol intake status among smoking quit-
ters or the insignificant interaction between drinking and
quitting smoking compared with the significant increase
in risk of MetS among quitters who drank alcohol shown
in Table 6 might be attributable to the relatively small
number of the subjects who quitted smoking and drank
alcohol. Meanwhile, whereas recent reports indicate the
harmful effect of alcohol intake on MetS, the majority of
the reports also support the potential beneficial effect of
Table 4: Multiple linear regression coefficients of smoking cessation for changes in metabolic syndrome parameters after smoking 
cessation adjusted by change in body mass index.
Men Women Total
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
All Subjects
(quitter 558, non-quitter 5314)
HDL cholesterol (mg/dL) 3.4 (2.7, 4.1)*** 1.8 (-0.8, 4.5) 3.2 (2.6, 3.9)***
Fasting triglyceride (mg/dL) -8.2 (-15.5, -0.9)* 4.0 (-9.2, 17.3) -7.1 (-13.9, -0.3)*
Fasting serum glucose (mg/dL) 1.8 (1.2, 2.5)*** 2.4 (0.3, 4.4)* 1.9 (1.2, 2.5)***
Systolic blood pressure (mmHg) 1.5 (1.0, 2.0)*** -0.5 (-4.1, 3.1) 2.9 (1.8, 4.0)***
Diastolic blood pressure (mmHg) 2.1 (1.2, 3.0)*** 0.0 (-2.9, 2.8) 1.9 (1.1, 2.7)***
MetS
(quitter 33, non-quitter 152)
HDL cholesterol (mg/dL) 4.1 (1.5, 6.6)** 39.1 (-774.3, 852.4) 4.2 (1.7, 6.8)**
Fasting triglyceride (mg/dL) -34.7 (-70.6, 1.2) 90.2 (-2383.4, 2563.9) -36.5 (-72.0, -1.1)*
Fasting serum glucose (mg/dL) 2.0 (-1.0, 4.9) 37.7 (-1304.6, 1379.9) 2.1 (-0.8, 5.1)
Systolic blood pressure (mmHg) 2.6 (-3.0, 8.2) -33.6 (-216.6, 149.4) 2.5 (-3.1, 8.0)
Diastolic blood pressure (mmHg) 1.8 (-2.4, 5.9) 47.2 (-720.1, 814.4) 2.0 (-2.1, 6.1)
without MetS
(quitter 525, non-quitter 5162)
HDL cholesterol (mg/dL) 3.3 (2.6, 4.0)*** 1.6 (-1.1, 4.3) 3.2 (2.5, 3.9)***
Fasting triglyceride (mg/dL) -7.2 (-14.6, 0.3) 5.2 (-8.2, 18.5) -6.0 (-13.0, 0.9)
Fasting serum glucose (mg/dL) 1.7 (1.0, 2.4)*** 2.1 (0.1, 4.2)* 1.7 (1.1, 2.4)***
Systolic blood pressure (mmHg) 3.2 (2.0, 4.3)*** -0.5 (-4.1, 3.2) 2.8 (1.7, 4.0)***
Diastolic blood pressure (mmHg) 2.1 (1.2, 3.0)*** -0.3 (-3.2, 2.6) 1.8 (1.0, 2.7)***
Coefficients are adjusted for sex, age and change in BMI by multiple linear regression.
95% CIs are shown in parentheses.
*: P < 0.05, **: P < 0.01, ***:P < 0.001.BMC Public Health 2009, 9:263 http://www.biomedcentral.com/1471-2458/9/263
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alcohol intake, especially in mild to moderate amount of
alcohol consumption [5,6,23]. This beneficial effect of
alcohol intake was not detected in this study; however,
there is a possibility that additional analyses according to
the amount of alcohol intake might provide such evi-
dence, although they could not be performed because the
information of the actual amount of alcohol intake was
not available in the present study. Further examination
with larger number of subjects or detailed information of
alcohol intake is required to clarify the precise effect of
alcohol intake on MetS among smoking quitters.
In Table 3 and 4 it is indicated that smoking cessation in
the subjects developing MetS is associated with a benefi-
cial effect on HDL-C and TG, which appear to be in con-
trast with the general result of this study i.e. smoking
cessation increases the risk of MetS. This discrepancy
would be due to the existence of a few quitters developing
MetS whose TG levels greatly decreased (TG levels
decreased in 13 of 33 quitters developing MetS, among
whom TG decreased more than 300 mg/dL in two quit-
ters) compared with the small increase among the rest of
the quitters (less than 200 mg/dL increase in 20 of 33
quitters). Those subjects with greater decrease in TG levels
would be the early appearance of the beneficial effect of
quitting smoking, while the TG levels still increased in
nearly two-thirds (20 of 33) of the quitters developing
MetS. The beneficial effect of smoking cessation on HDL-
C seemed to have been offset by these increases in TG lev-
els.
There are several limitations in this study. First, the impre-
cise definition of smoking and smoking cessation and the
lack of quantification of smoking and alcohol intake are
the shortcomings of this study. Other lifestyle factors
Table 5: Components of metabolic syndrome criteria 
(hypertension: H, hyperlipidemia: L, impaired fasting glucose: G) 
among 33 examinees (32 males and one female) who became 
metabolic syndrome after smoking cessation.
BMI < 25 before cessation (n = 20)
Component before cessation Component after cessation n
HLGH L G
---+ + - 2
---- + + 1
---+ + + 1
+--+ + - 2
+--+ - + 1
-+-+ + - 2
-+-+ - + 1
-+-- + + 1
--+ + - + 1
--+- + + 2
++-+ +- 4
++-+-+ 1
++-+ + + 1
BMI ≥ 25 before cessation (n = 13)
Component before cessation Component after cessation n
HLGH L G
---+ - + 1
---- + + 2
---+ + + 1
+--+ + - 2
+--+ - + 1
-+-+ + - 4
--+ + - + 1
-+-+ + + 1
Table 6: Adjusted hazard ratio (aHR)a and 95% confidence 
intervals (95% CIs) of metabolic syndrome according to the 
combined status of smoking cessation and alcohol consumption.
Non-drinker Drinker
All Subjects
Non-quitters n 1380 3910
MetS 40 112
aHR 1 0.98
95% CI Reference 0.68–1.41
Quitters n 174 383
MetS 62 7
aHR 1.24 2.42b
95% CI 0.52–2.92 1.48–3.94***
Men
Non-quitters n 1216 3734
MetS 38 107
aHR 1 0.94
95% CI Reference 0.65–1.36
Quitters n 137 358
MetS 52 7
aHR 1.18 2.46c
95% CI 0.46–2.99 1.50–4.02***
Women
Non-quitters n 164 176
MetS 25
aHR 1 2.59
95% CI Reference 0.50–13.34
Quitters n 37 25
MetS 10
aHR 2.13 0
95% CI 0.19–23.56 -
a Adjusted for sex and age (all subjects), or age (men and women).
b Interaction = 2.03 (P = 0.146).
c Interaction = 2.27 (P = 0.116)
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which might be associated with the risk of MetS like exer-
cise amount or frequency were not available, which also
decreased the potential of this study. The lack of informa-
tion about blood pressure medication at baseline is
another important limitation. Further investigations with
better study design are expected. The second limitation is
concerning the definition of MetS. We adopted the Japa-
nese criteria defined by JASSO [3], because it is popular
and widely used in practice in Japan, and is shown to be
as predictable of CHD in Japanese as other world's three
representative criteria (the National Cholesterol Educa-
tion Program Adult Treatment Panel III (NCEP-ATP III),
American Heart Association in conjunction with the
National Heart, Lung, and Blood Institute (AHA/NHLBI),
and International diabetes federation (IDF) criteria) [25],
and some study demonstrate that Japanese criteria corre-
late better with CHD in elderly Asian women than these
three criteria [26], although we should recognize that this
Japanese definition is still one of several premature defini-
tions requiring verification with further prognostic evi-
dence. In the Japanese criteria obesity is defined with WC,
but in this study we used BMI instead of WC. In some
study, the effects of WC and BMI on cardiovascular risks
are similar, but not completely the same; increases in BMI
were associated with increased risk of hypertension, dysl-
ipidemia and MetS as well as WC, while risk of diabetes
was only associated with WC [27], suggesting that we have
to be careful in interpreting the results. Meanwhile, a
number of studies have shown that BMI is an effective pre-
dictor of type 2 DM or other metabolic disturbances [28],
and JASSO recently reported subjects with multiple meta-
bolic risk factors can be detected with the best combina-
tion of sensitivity and specificity by a BMI of 25 [29].
Although the 2-hour oral glucose tolerance test (2-h
OGTT) is commonly used for accurate diagnosis of
impaired fasting glucose, we defined impaired fasting glu-
cose as FSG ≥ 110 mg/dL in this study because the 2-h
OGTT was not carried out in most of the study subjects,
and it is not part of the NCEP-ATP III, AHA/NHLBI, IDF
or Japanese criteria of MetS. A subset of analyses in which
BMI is not used as part of the definition of MetS, in which
changes in MetS incidence between quitters and non-quit-
ters are adjusted by changes in BMI, might reveal more of
the effects of quitting smoking on the risk of MetS inde-
pendent of BMI change; however, we could not perform
these analyses because there were no other effective ways
to measure obesity (such as WC) in this dataset. Further
investigation of the effects of smoking cessation on the
risk of MetS with the definition not including BMI is
required. Another limitation is concerning the sample size
of this study. The sample size for those who smoked at
baseline but quitted smoking at the subsequent checkup,
as well as the number of women subjects or the number
of subjects used in the analyses of smoking cessation with
the risk of MetS over longer follow-up times, is rather
small to have a reliable finding, which requires further
investigation of this association with a larger number of
study subjects in the near future.
Our finding revealed that smoking cessation significantly
raised the risk of MetS, and alcohol intake might add to
this risk elevation in male smoking quitter. The present
study gives us the lesson that medical practitioners should
take care of smoking quitters not to gain weight or not to
suffer from MetS, by giving them instructions about
appropriate amount of exercise, proper energy intake or
calorie restriction, along with alcohol cessation.
Our additional analyses of longer follow-up periods
showed that smoking cessation had no significant long-
term influence on the risk of MetS, suggesting that any
detrimental effect of quitting smoking on the risk of MetS
only happens over a short period; however, we should be
aware of this possibility when promoting smoking cessa-
tion. Obviously, the clear beneficial effect of quitting
smoking on the prevention of cancer in various organs,
cardiovascular diseases in addition to MetS [3] is more
important than avoiding this transitory potential for
MetS.
Conclusion
This study revealed that smoking cessation transiently
increased the risk of MetS, and alcohol intake might add
to it. Further investigation with better study design or in
other study groups is required to confirm our findings.
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